Table 3. List of target agents approved for their use in cancer patients and related costs.

BCC = Basal-cell Carcinoma; GIST = Gastrointestinal Stromal Tumor; NSCLC = Non Small Cell Lung Cancer; RCC = Renal Cell Carcinoma.

Target Agent	Cancer Type	Monthly cost ($)	Cost per PFS ($)
Abiraterone acetate (first line therapy)	Prostate	8,627	142,346
Abiraterone acetate (successive line-therapy)	Prostate	8,627	48,311
Afatinib	NSCLC	6,970	77,367
Bevacizumab	Glioblastoma	4,400	24,640
Bevacizumab	RCC	4,400	44,880
Bevacizumab (first line therapy)	Colorectal	2,680	28,408
Bevacizumab (successive line-therapy)	Colorectal	2,680	15,276
Cabozantinib	Thyroid	14,300	160,160
Cetuximab	Head and Neck	7,000	38,500
Cobimetinib + Vemurafenib	Melanoma	26,300	260,370
Crizotinib	NSCLC	11,500	88,550
Enzalutamide (first line therapy)	Prostate	7,450	61,835
Enzalutamide (successive line-therapy)	Prostate	7,450	42,465
Erlotinib	Pancreas	2,450	9,310
Erlotinib (first line thrapy)	NSCLC	3,000	29,100
Erlotinib (maintainance therapy)	NSCLC	3,000	8,700
Everolimus	Breast	7,000	54,600
Lenvatinib	Thyroid	13,945	204,992
Nivolumab	Squamous NSCLC	12,600	44,100
Nivolumab	Non-Squamous NSCLC	12,600	28,980
Nivolumab	Melanoma	12,600	64,260
Nivolumab	RCC	6,984	32,126
Palbociclib (+letrozole)	Breast	9,850	198,970
Palbociclib (+fulvestrant)	Breast	9,850	90,620
Pembrolizumab	Melanoma	23,017	94,370
Ramucirumab	Gastric	13,000	27,300
Ramucirumab	NSCLC	11,000	49,500
Ramucirumab	Colorectal	13,000	74,100
Regorafenib	Colorectal	7,600	14,440
Sonidegib	BCC	12,000	157,200
Sorafenib	RCC	6,600	36,300
Sunitinib	RCC	7,000	77,000
Sunitinib	GIST	7,000	44,800
T-DM1	Breast	9,800	94,080
Temsirolimus	RCC	2,960	11,248
Trametinib + Dabrafenib	Melanoma	16,300	151,590
Ziv-Aflibercept	Colorectal	11,000	75,900